Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 13/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.74 |
| ▸ | MAPKAPK3 | Q16644 | 6/20 | 0.74 |
| ▸ | MAPK6 | Q16659 | 6/20 | 0.74 |
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.74 |
| ▸ | MAPKAPK5 | Q8IW41 | 3/20 | 0.74 |
| ▸ | TTK | P33981 | 2/20 | 0.67 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.67 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.62 |
| ▸ | PIM1 | P11309 | 2/20 | 0.59 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22819384 | 0.85 | MAP2K4 (1.00) | MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL8437332 | 0.82 | MAP2K4 (0.84) | MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL22801693 | 0.81 | MAP2K4 (0.76) | MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL5374481 | 0.80 | MAP2K4 (0.67) | MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL5382810 | 0.79 | MAP2K4 (0.65) | MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL5801740 | 0.79 | MAP2K4 (0.65) | MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL5377609 | 0.79 | MAP2K4 (0.65) | MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL22801653 | 0.78 | MAP2K4 (0.64) | MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL5377947 | 0.78 | MAP2K4 (0.63) | MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL28520483 | 0.77 | MAP3K5 (1.00) | MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370770-B2 | 3-arylindazoles as selective MEK4 inhibitors | NORTHWESTERN UNIVERSITY (US) | 2022-06-28 | — | — | US | disclosed |
| US-20200399241-A1 | 3-ARYLINDAZOLES AS SELECTIVE MEK4 INHIBITORS | NORTHWESTERN UNIVERSITY (US) | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399241-A1 | 3-ARYLINDAZOLES AS SELECTIVE MEK4 INHIBITORS | MAP4K3, MAPK4, MAP3K4 | MAP2K4 39/4885MAPK1 32/4885MAPKAPK3 24/4885 |
| US-11370770-B2 | 3-arylindazoles as selective MEK4 inhibitors | MAP4K3, MAPK4, MAP3K4 | MAP2K4 39/4885MAPK1 32/4885MAPKAPK3 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.